title: Major Highlights of the CAR-TCR Summit, Boston, 2016.
abstract: Cellular immunotherapies such as CAR-T cell therapy and TCR-T cell therapy are relatively new, highly promising approaches for the treatment of cancer. In CAR-T cell therapy, a patient's T cells are engineered to express chimeric antigen receptors targeting tumor-associated cell surface antigens. In TCR-T cell therapy, the patient's T cells are engineered to express receptors targeting intracellular antigens. This report will summarize presentations from the recent CAR-TCR summit in Boston on September 13-16, 2016. These presentations were given by leaders in the field and many were divided into three streams: Discovery and Genetic T Cell Engineering; Translation and Clinical Development; and Manufacturing, Supply Chain and Commercialization. The report summarizes major pharmaceutical companies developing these novel therapies and provides challenges and perspectives for future therapeutic developments.
authors.affiliation: Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA, 94806. United States.
authors.forename: Vita
authors.initials: V
authors.lastname: Golubovskaya
authors.affiliation: Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA, 94806. United States.
authors.forename: Robert
authors.initials: R
authors.lastname: Berahovich
authors.affiliation: Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA, 94806. United States.
authors.forename: Shirley
authors.initials: S
authors.lastname: Xu
authors.affiliation: Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA, 94806. United States.
authors.forename: Hizkia
authors.initials: H
authors.lastname: Harto
authors.affiliation: Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA, 94806. United States.
authors.forename: Lijun
authors.initials: L
authors.lastname: Wu
mesh_terms: D001900:Boston; D006801:Humans; D007167:Immunotherapy; D009369:Neoplasms / Q000628:therapy*; D011946:Receptors, Antigen / Q000276:immunology*
chemical_list: D011946:Receptors, Antigen
keywords: Chimeric antigen receptor; T-cell enginering; cancer; cytokine; immunotherapy; tumor antigen